Evaluating the antifracture efficacy of bisphosphonates.
Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...
المؤلفون الرئيسيون: | Pazianas, M, Epstein, S, Zaidi, M |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2009
|
مواد مشابهة
-
Antifracture agents for prostate cancer patients on androgen deprivation therapy
حسب: Bhupendra P Singh, وآخرون
منشور في: (2010-01-01) -
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
حسب: Angelo Fassio, وآخرون
منشور في: (2024-04-01) -
Safety of bisphosphonates.
حسب: Pazianas, M, وآخرون
منشور في: (2011) -
Bisphosphonates and bone quality.
حسب: Pazianas, M, وآخرون
منشور في: (2014) -
Atrial fibrillation and bisphosphonate therapy.
حسب: Pazianas, M, وآخرون
منشور في: (2010)